The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients

Publisher： Karger

E-ISSN： 1423-0232|68|2-3|212-216

ISSN： 0030-2414

Source： Oncology, Vol.68, Iss.2-3, 2005-07, pp. : 212-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gefitinib in Combination with 5-Fluorouracil (5-FU)/Folinic Acid and Irinotecan in Patients with 5-FU/Oxaliplatin- Refractory Colorectal Cancer: A Phase I/II Study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO)

By  

Oncology Research and Treatment, Vol. 29, Iss. 12, 2006-12 ,pp. : 563-567

Karger

Access to resources Recommend Favorite

Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 254-265

Karger

Access to resources Recommend Favorite

Continuous Infusion of Oxaliplatin plus Chronomodulated Capecitabine in 5-Fluorouracil- and Irinotecan-Resistant Advanced Colorectal Cancer Patients

By  

Oncology, Vol. 69, Iss. 1, 2005-09 ,pp. : 27-34

Karger

Access to resources Recommend Favorite

Irinotecan and Mitomycin C in 5-Fluorouracil-Refractory Colorectal Cancer Patients

By  

Oncology, Vol. 60, Iss. 2, 2001-02 ,pp. : 127-133

Karger

Access to resources Recommend Favorite

Multicenter Phase I Study of Irinotecan plus Raltitrexed in Patients with 5-Fluorouracil-Refractory Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 42-47

Karger

Access to resources Recommend Favorite